CY1118198T1 - Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων - Google Patents
Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχωνInfo
- Publication number
- CY1118198T1 CY1118198T1 CY20161101130T CY161101130T CY1118198T1 CY 1118198 T1 CY1118198 T1 CY 1118198T1 CY 20161101130 T CY20161101130 T CY 20161101130T CY 161101130 T CY161101130 T CY 161101130T CY 1118198 T1 CY1118198 T1 CY 1118198T1
- Authority
- CY
- Cyprus
- Prior art keywords
- treatment
- neurological disorders
- pantothenic
- products
- kinase
- Prior art date
Links
- 208000012902 Nervous system disease Diseases 0.000 title abstract 3
- 208000025966 Neurological disease Diseases 0.000 title abstract 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical class OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 abstract 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
- C07F9/242—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyaryl compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/222—Amides of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/22—Amides of acids of phosphorus
- C07F9/24—Esteramides
- C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
- C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261639602P | 2012-04-27 | 2012-04-27 | |
| PCT/US2013/038458 WO2013163576A1 (en) | 2012-04-27 | 2013-04-26 | Pantothenate derivatives for the treatment of neurologic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118198T1 true CY1118198T1 (el) | 2017-06-28 |
Family
ID=48428654
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101130T CY1118198T1 (el) | 2012-04-27 | 2016-11-04 | Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων |
| CY20191100156T CY1121238T1 (el) | 2012-04-27 | 2019-02-05 | Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100156T CY1121238T1 (el) | 2012-04-27 | 2019-02-05 | Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US8673883B2 (enExample) |
| EP (3) | EP3112372B1 (enExample) |
| JP (3) | JP6254151B2 (enExample) |
| KR (1) | KR20150035550A (enExample) |
| CN (2) | CN106977544B (enExample) |
| AU (3) | AU2013251345B2 (enExample) |
| BR (1) | BR112014026817A2 (enExample) |
| CA (1) | CA2879314A1 (enExample) |
| CY (2) | CY1118198T1 (enExample) |
| DK (2) | DK2841438T3 (enExample) |
| ES (2) | ES2708813T3 (enExample) |
| HR (2) | HRP20161389T1 (enExample) |
| HU (2) | HUE042199T2 (enExample) |
| IN (1) | IN2014DN09584A (enExample) |
| LT (2) | LT3112372T (enExample) |
| MX (1) | MX360149B (enExample) |
| PL (2) | PL3112372T3 (enExample) |
| PT (2) | PT3112372T (enExample) |
| RS (2) | RS55319B1 (enExample) |
| RU (2) | RU2653497C2 (enExample) |
| SI (2) | SI3112372T1 (enExample) |
| SM (2) | SMT201900007T1 (enExample) |
| TR (1) | TR201819263T4 (enExample) |
| WO (1) | WO2013163576A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3112372T1 (sl) * | 2012-04-27 | 2019-04-30 | Retrophin, Inc. | Derivati pantotenata za zdravljenje nevroloških motenj |
| US9896464B2 (en) | 2013-10-25 | 2018-02-20 | Retrophin, Inc. | Pantothenate derivatives for the treatment of neurological disorders |
| EP2868662A1 (en) | 2013-11-04 | 2015-05-06 | Acies Bio d.o.o. | Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds |
| EP3386995A1 (en) * | 2015-12-08 | 2018-10-17 | Retrophin, Inc. | Cyclic phosphates and cyclic phosphoramidates for the treatment of neurologic disorders |
| MX2019009342A (es) * | 2017-02-07 | 2019-10-02 | Retrophin Inc | Formulaciones de fosmetpantotenato solido. |
| US12065404B2 (en) | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2676976A (en) | 1950-12-04 | 1954-04-27 | Nat Res Dev | Synthesis of pantothenic acid-4' phosphate |
| US2870188A (en) | 1955-10-03 | 1959-01-20 | Hoffmann La Roche | Process for the manufacture of pantothenic acid 4'-phosphate and its salts |
| RU2002110463A (ru) * | 1999-09-21 | 2004-02-27 | Басф Акциенгезелльшафт (De) | Способ и микроорганизмы для получения пантосоединений |
| AU2002326412A1 (en) | 2001-07-20 | 2003-03-03 | Oregon Health And Science University | Novel human nucleic acids encoding a pantothenate kinase and methods of use |
| US20060099692A1 (en) * | 2002-07-03 | 2006-05-11 | Yocum R R | Microorganisms and processes for enhanced production of pantothenate |
| CN101287472B (zh) | 2005-08-15 | 2011-10-12 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的4'-取代前核苷酸的氨基磷酸酯类化合物 |
| SI3112372T1 (sl) * | 2012-04-27 | 2019-04-30 | Retrophin, Inc. | Derivati pantotenata za zdravljenje nevroloških motenj |
-
2013
- 2013-04-26 SI SI201331263T patent/SI3112372T1/sl unknown
- 2013-04-26 RU RU2014147739A patent/RU2653497C2/ru not_active IP Right Cessation
- 2013-04-26 RU RU2018112720A patent/RU2018112720A/ru not_active Application Discontinuation
- 2013-04-26 PT PT16001739T patent/PT3112372T/pt unknown
- 2013-04-26 IN IN9584DEN2014 patent/IN2014DN09584A/en unknown
- 2013-04-26 CN CN201611221824.7A patent/CN106977544B/zh not_active Expired - Fee Related
- 2013-04-26 MX MX2014013048A patent/MX360149B/es active IP Right Grant
- 2013-04-26 CA CA2879314A patent/CA2879314A1/en not_active Abandoned
- 2013-04-26 ES ES16001739T patent/ES2708813T3/es active Active
- 2013-04-26 JP JP2015509192A patent/JP6254151B2/ja not_active Expired - Fee Related
- 2013-04-26 SI SI201330307A patent/SI2841438T1/sl unknown
- 2013-04-26 LT LTEP16001739.8T patent/LT3112372T/lt unknown
- 2013-04-26 HU HUE16001739A patent/HUE042199T2/hu unknown
- 2013-04-26 BR BR112014026817A patent/BR112014026817A2/pt not_active Application Discontinuation
- 2013-04-26 EP EP16001739.8A patent/EP3112372B1/en active Active
- 2013-04-26 PT PT137222014T patent/PT2841438T/pt unknown
- 2013-04-26 HR HRP20161389TT patent/HRP20161389T1/hr unknown
- 2013-04-26 ES ES13722201.4T patent/ES2600179T3/es active Active
- 2013-04-26 DK DK13722201.4T patent/DK2841438T3/en active
- 2013-04-26 PL PL16001739T patent/PL3112372T3/pl unknown
- 2013-04-26 DK DK16001739.8T patent/DK3112372T3/en active
- 2013-04-26 US US13/871,691 patent/US8673883B2/en not_active Expired - Fee Related
- 2013-04-26 RS RS20160939A patent/RS55319B1/sr unknown
- 2013-04-26 TR TR2018/19263T patent/TR201819263T4/tr unknown
- 2013-04-26 WO PCT/US2013/038458 patent/WO2013163576A1/en not_active Ceased
- 2013-04-26 LT LTEP13722201.4T patent/LT2841438T/lt unknown
- 2013-04-26 PL PL13722201T patent/PL2841438T3/pl unknown
- 2013-04-26 SM SM20190007T patent/SMT201900007T1/it unknown
- 2013-04-26 CN CN201380033271.0A patent/CN104520307B/zh not_active Expired - Fee Related
- 2013-04-26 HU HUE13722201A patent/HUE029474T2/en unknown
- 2013-04-26 RS RS20190049A patent/RS58336B1/sr unknown
- 2013-04-26 EP EP13722201.4A patent/EP2841438B1/en active Active
- 2013-04-26 AU AU2013251345A patent/AU2013251345B2/en not_active Ceased
- 2013-04-26 EP EP18201414.2A patent/EP3489248A1/en not_active Withdrawn
- 2013-04-26 KR KR20147033141A patent/KR20150035550A/ko not_active Abandoned
-
2014
- 2014-01-16 US US14/157,173 patent/US9181286B2/en not_active Expired - Fee Related
-
2015
- 2015-09-30 US US14/871,450 patent/US9629862B2/en not_active Expired - Fee Related
-
2016
- 2016-11-03 SM SM201600395T patent/SMT201600395B/it unknown
- 2016-11-04 CY CY20161101130T patent/CY1118198T1/el unknown
-
2017
- 2017-03-22 JP JP2017055792A patent/JP6560284B2/ja not_active Expired - Fee Related
- 2017-10-04 AU AU2017239508A patent/AU2017239508C1/en not_active Ceased
-
2019
- 2019-01-04 HR HRP20190038TT patent/HRP20190038T1/hr unknown
- 2019-02-05 CY CY20191100156T patent/CY1121238T1/el unknown
- 2019-07-18 JP JP2019132651A patent/JP2019206553A/ja active Pending
- 2019-08-20 AU AU2019219733A patent/AU2019219733A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121238T1 (el) | Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων | |
| TN2015000278A1 (en) | Autotaxin inhibitors | |
| EA201400833A1 (ru) | Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| BR112015026023A2 (pt) | derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1 | |
| CY1118680T1 (el) | Φαρμακευτικη συνθεση | |
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| PH12016500094A1 (en) | Autotaxin inhibitors | |
| CY1116987T1 (el) | Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις | |
| UA113651C2 (xx) | Макроциклічні пурини для лікування вірусних інфекцій | |
| HUE060743T2 (hu) | Gyógyszerészeti kompozíciók, amelyek tartalmaznak imidazothiadiazol- és imidazopiridazinszármazékokat mint proteáz aktívált receptor 4 (PAR4) inhibitorokat trombocitaaggregációk kezelésére | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| EA201591527A1 (ru) | Новые производные пиридина | |
| CL2015002473A1 (es) | Derivados de 6-(5-hidroxi-1h-pirazol-1-il)nicotinamida y su uso como inhibidores de la phd. | |
| MX338515B (es) | Derivados de tetrahidroquinolina utiles como inhibidores de bromodominio. | |
| MY173521A (en) | Trpv4 antagonists | |
| EA201491376A1 (ru) | Производные 1h-пирроло[2,3-b]пиридина и их применение в качестве ингибиторов киназы | |
| PH12015501609A1 (en) | Phenicol antibacterials | |
| EA201600124A1 (ru) | Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| CY1117210T1 (el) | Παραγωγα 2-οξο-1-ιμιδαζολιδινυλ ιμιδαζοθειαδιαζολης | |
| CL2014002845A1 (es) | Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2. | |
| CY1120185T1 (el) | Υποκατεστημενα πυριδινικα παραγωγα χρησιμα ως αναστολεις c-fms κινασης | |
| CL2014001862A1 (es) | Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia. | |
| EA201400444A1 (ru) | Производные 2-оксопиперидинила | |
| MX366829B (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
| EA201600394A1 (ru) | Трициклические соединения пиперидина |